Blood doping is any method or substance used to artificially increase the number of red blood cells in an athlete’s body, boosting the amount of oxygen that reaches working muscles. It’s banned in all competitive sports and carries serious cardiovascular risks, including stroke and heart attack. The practice has been central to some of the biggest scandals in sports history, and anti-doping agencies now use sophisticated tracking systems to catch it.
How Blood Doping Works
Red blood cells carry oxygen from the lungs to muscles. During intense exercise, your muscles burn through oxygen rapidly, and the limiting factor in endurance performance is often how fast your blood can deliver more. Blood doping raises the total number of red blood cells circulating in your body, which increases the oxygen-carrying capacity of each heartbeat. The result is that muscles can sustain higher workloads for longer before fatigue sets in.
There are three main approaches: blood transfusions, hormone injections, and synthetic oxygen carriers. Each takes a different path to the same outcome: more oxygen reaching muscles during exercise.
Blood Transfusions
The most straightforward method is simply adding more blood. In an autologous transfusion, an athlete withdraws their own blood weeks or months before a competition, stores it, and then reinfuses it close to race day. The body naturally replaces the withdrawn blood during the recovery period, so when the stored blood goes back in, the athlete temporarily has a higher red blood cell count than normal.
Homologous transfusions use blood from another person, typically someone with the same blood type. This approach skips the weeks-long recovery period but introduces a different set of problems, including the risk of transfusion reactions and infectious disease transmission. It’s also easier to detect, since foreign blood cells carry different surface proteins that lab tests can identify.
Storage matters significantly. Blood kept refrigerated at standard temperatures lasts 35 to 42 days, but the red blood cells gradually lose quality during that window. They become stiffer and less able to squeeze through tiny capillaries, which is exactly where oxygen delivery to muscles happens. Freezing blood (cryopreservation) halts this aging process and allows storage for up to ten years, preserving the cells’ flexibility and function. Research shows athletes need at least four weeks of recovery after withdrawing blood before their body fully replenishes what was taken, making the timing of the whole process a careful balancing act.
EPO and Hormone-Based Methods
Erythropoietin, better known as EPO, is a hormone your kidneys naturally produce to signal your bone marrow to make more red blood cells. Synthetic versions were developed to treat severe anemia in kidney disease patients. When healthy athletes inject synthetic EPO, their bone marrow goes into overdrive, producing far more red blood cells than the body needs.
This raises both hemoglobin (the oxygen-carrying protein inside red blood cells) and hematocrit (the percentage of blood volume occupied by red blood cells). In medical settings, pushing hemoglobin above 11 grams per deciliter is associated with a higher risk of death, serious cardiovascular events, and stroke. Athletes using EPO often push well beyond that threshold, thickening their blood to dangerous levels.
EPO became infamous in professional cycling during the 1990s, when its use was widespread and largely undetectable. It offered the performance benefits of a blood transfusion without the logistical nightmare of secretly storing and reinfusing blood bags.
Synthetic Oxygen Carriers
A third category bypasses red blood cells entirely. Synthetic oxygen carriers are chemical products designed to dissolve and transport oxygen through the bloodstream. Two main types exist: hemoglobin-based carriers, which use modified hemoglobin outside of red blood cells, and perfluorocarbon-based carriers, which are entirely synthetic molecules that physically dissolve oxygen depending on pressure conditions.
Perfluorocarbon carriers have an unusual advantage: because they’re chemically inert, they keep working even in the presence of carbon monoxide or other toxins that would disable natural hemoglobin. Their medical applications include treating decompression sickness and carbon monoxide poisoning. For doping purposes, they represent a way to boost oxygen delivery without changing red blood cell counts at all, making detection through standard blood tests more difficult. However, these products remain largely experimental, with limited pharmaceutical approval worldwide.
Health Risks
The core danger of blood doping comes down to viscosity. More red blood cells means thicker blood. Thicker blood is harder to pump, forces the heart to work harder, and is more likely to form clots. The Mayo Clinic lists stroke, heart attack, and pulmonary embolism (a blood clot in the lungs) among the serious risks of EPO-based doping. These risks don’t disappear after competition. Athletes who dope chronically subject their cardiovascular system to repeated stress that can cause lasting damage.
Blood transfusions carry their own set of complications. Autologous transfusions risk bacterial contamination if blood isn’t stored properly. Homologous transfusions add the possibility of allergic reactions, immune responses, and transmission of bloodborne infections. Reinfusing blood that has degraded during storage can trigger the destruction of those cells in the bloodstream, releasing harmful byproducts.
Several unexplained deaths among professional cyclists in the late 1980s and 1990s were widely attributed to EPO use, occurring during sleep when heart rate drops and already-thick blood becomes even harder to circulate.
How Anti-Doping Agencies Detect It
Direct detection of blood doping depends on the method. Synthetic EPO can be distinguished from natural EPO through urine and blood tests, though athletes have learned to microdose to keep levels low enough to avoid triggering a positive result. Homologous transfusions are detectable through flow cytometry, which identifies foreign blood cell populations. Autologous transfusions remain the hardest to catch directly, since the reinfused blood is the athlete’s own.
To address this gap, the World Anti-Doping Agency (WADA) introduced the Athlete Biological Passport, a longitudinal tracking system that monitors each athlete’s blood values over time. Rather than looking for a banned substance in a single sample, it builds an individual profile and flags suspicious changes. The system tracks hemoglobin concentration and a metric called the OFF-score (a stimulation index reflecting how actively the body is producing new red blood cells) as primary markers. Reticulocyte percentage, which measures the proportion of young, newly produced red blood cells, serves as a secondary marker.
The logic is straightforward. After a blood transfusion, hemoglobin jumps while reticulocyte production drops, because the body senses it has plenty of red blood cells and dials back production. After EPO use, both hemoglobin and reticulocyte counts spike. These patterns are difficult to mimic naturally, and when an athlete’s values fall outside their established personal range, anti-doping authorities can open an investigation even without identifying a specific substance.
What WADA Currently Prohibits
WADA’s Prohibited List bans the administration or reintroduction of any quantity of autologous, homologous, or heterologous blood or red blood cell products into the circulatory system. Even withdrawing blood or blood components is prohibited unless it’s for medical testing or donation at an accredited collection center. EPO and all related erythropoiesis-stimulating agents are also banned, as are synthetic oxygen carriers. The prohibitions apply both in and out of competition, year-round.